Eagle Pharmaceuticals,Inc. (NYSE:TEVA) Files An 8-K Financial Statements and Exhibits

Item 9.01 of the Initial 8-K to provide the financial statements
and financial information described below, which were not filed
with the Initial 8-K and are permitted to be filed by amendment
no later than seventy-one (71) calendar days after November22,
2016, i.e. the date that the Initial 8-K was required to be filed
with the Commission.

Item 9.01 Financial Statements and
Exhibits.

(a)Financial statements of businesses acquired.

The audited balance sheets of Arsia as of December31, 2015 and
December31, 2014 and audited statements of operations, changes in
stockholders (deficit) equity, and cash flows for the years ended
December31, 2015 and December31, 2014, and related notes, are
filed as Exhibit99.1 to this Current Report on Form8-K/A and
incorporated herein by reference.

Also included as part of and filed as Exhibit99.1 to this Current
Report on Form8-K/A and incorporated herein by reference are the
unaudited balance sheet of Arsia as of September30, 2016,
unaudited statements of operations and statements of cash flows
for the nine months ended September30, 2016 and September30,
2015, and unaudited statement of stockholders (deficit) equity
for the nine months ended September30, 2016, and related notes.

(b)Pro forma financial information.

The Companys unaudited pro forma condensed combined balance sheet
as of September30, 2016 and unaudited pro forma condensed
combined statements of operations for the nine months ended
September30, 2016, and for the year ended December31, 2015, and
related notes, showing the pro forma effects of the Companys
acquisition of Arsia, are filed as Exhibit99.2 to this Current
Report on Form8-K/A and incorporated herein by reference.

(d)Exhibits.

About Eagle Pharmaceuticals, Inc. (NYSE:TEVA)

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules. Its central nervous system (CNS) portfolio includes Copaxone for the treatment of multiple sclerosis, Azilect for the treatment of the symptoms of Parkinson’s disease and Nuvigil for the treatment of sleep disorders, as well as several therapies for the treatment of pain care. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo in the United States and Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio outside the United States. Its women’s health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.

Eagle Pharmaceuticals, Inc. (NYSE:TEVA) Recent Trading Information

Eagle Pharmaceuticals, Inc. (NYSE:TEVA) closed its last trading session up +1.26 at 34.69 with 17,244,517 shares trading hands.